pI: 6.3466 |
Length (AA): 248 |
MW (Da): 27935 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 247 | 1n55 (A) | 3 | 249 | 46.00 | 0 | 1 | 1.64 | -2.15 |
3 | 248 | 1o5x (A) | 3 | 248 | 99.99 | 0 | 1 | 2.28 | -2.56 |
3 | 248 | 5bnk (B) | 3 | 248 | 99.99 | 0 | 1 | 2.27014 | -2.26 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, merozoite, sporozoite, early ring, early schizont, early trophozoite, late ring, late schizont, late trophozoite, Ring, Sporozoite, Male Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | gametocyte. | PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Oocyst, Female Gametocyte. | Zanghi G Lasonder E |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Ortholog group members (OG5_127002)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G21170 | triosephosphate isomerase |
Arabidopsis thaliana | AT3G55440 | triosephosphate isomerase |
Babesia bovis | BBOV_II001220 | triosephosphate isomerase protein, putative |
Brugia malayi | Bm1_29130 | triosephosphate isomerase |
Candida albicans | CaO19.6745 | similar to S. cerevisiae TPI1 (YDR050C) triose phosphate isomerase |
Candida albicans | CaO19.14037 | similar to S. cerevisiae TPI1 (YDR050C) triose phosphate isomerase |
Caenorhabditis elegans | CELE_Y17G7B.7 | Protein TPI-1 |
Cryptosporidium hominis | Chro.10337 | triose-phosphate isomerase |
Cryptosporidium parvum | cgd1_3040 | triosephosphate isomerase |
Chlamydia trachomatis | CT_328 | triosephosphate isomerase |
Dictyostelium discoideum | DDB_G0274471 | triose phosphate isomerase |
Drosophila melanogaster | Dmel_CG2171 | Triose phosphate isomerase |
Escherichia coli | b3919 | triosephosphate isomerase |
Echinococcus granulosus | EgrG_000416400 | triosephosphate isomerase |
Entamoeba histolytica | EHI_056480 | triosephosphate isomerase |
Echinococcus multilocularis | EmuJ_000416400 | triosephosphate isomerase |
Giardia lamblia | GL50803_93938 | Triosephosphate isomerase, cytosolic |
Homo sapiens | ENSG00000111669 | triosephosphate isomerase 1 |
Leishmania braziliensis | LbrM.20.5360 | triosephosphate isomerase |
Leishmania donovani | LdBPK_240870.1 | triosephosphate isomerase |
Leishmania infantum | LinJ.24.0870 | triosephosphate isomerase |
Leishmania major | LmjF.24.0850 | triosephosphate isomerase |
Leishmania mexicana | LmxM.24.0850 | triosephosphate isomerase |
Loa Loa (eye worm) | LOAG_09607 | triosephosphate isomerase |
Mycobacterium leprae | ML0572 | Probable triosephosphate isomerase Tpi (TIM) |
Mus musculus | ensembl-mmu:ENSMUSG00000023456 | triosephosphate isomerase 1 |
Mycobacterium tuberculosis | Rv1438 | Probable triosephosphate isomerase Tpi (TIM) |
Mycobacterium ulcerans | MUL_1830 | triosephosphate isomerase |
Neospora caninum | NCLIV_033270 | hypothetical protein |
Neospora caninum | NCLIV_046900 | hypothetical protein |
Oryza sativa | 4327400 | Os01g0841600 |
Oryza sativa | 4347691 | Os09g0535000 |
Oryza sativa | 4325211 | Os01g0147900 |
Plasmodium berghei | PBANKA_1303800 | triosephosphate isomerase, putative |
Plasmodium falciparum | PF3D7_1439900 | triosephosphate isomerase |
Plasmodium knowlesi | PKNH_1242400 | triosephosphate isomerase, putative |
Plasmodium vivax | PVX_118495 | triosephosphate isomerase, putative |
Plasmodium yoelii | PY04306 | triosephosphate isomerase |
Saccharomyces cerevisiae | YDR050C | triose-phosphate isomerase TPI1 |
Schistosoma japonicum | Sjp_0304690 | ko:K01803 triosephosphate isomerase (TIM) [EC5.3.1.1], putative |
Schistosoma mansoni | Smp_003990 | triosephosphate isomerase |
Schmidtea mediterranea | mk4.001789.01 | Triosephosphate isomerase |
Schmidtea mediterranea | mk4.034460.04 | Triosephosphate isomerase |
Schmidtea mediterranea | mk4.006707.00 | Triosephosphate isomerase |
Trypanosoma brucei gambiense | Tbg972.11.6230 | triosephosphate isomerase, putative |
Trypanosoma brucei | Tb927.11.5520 | triosephosphate isomerase |
Trypanosoma congolense | TcIL3000.11.5810 | triosephosphate isomerase, putative |
Trypanosoma cruzi | TcCLB.508647.200 | triosephosphate isomerase, putative |
Toxoplasma gondii | TGME49_225930 | triose-phosphate isomerase TPI-I |
Toxoplasma gondii | TGME49_233500 | triose-phosphate isomerase TPI-II |
Treponema pallidum | TP0537 | triosephosphate isomerase |
Theileria parva | TP04_0464 | triosephosphate isomerase, putative |
Trichomonas vaginalis | TVAG_497370 | triosephosphate isomerase, putative |
Trichomonas vaginalis | TVAG_096350 | triosephosphate isomerase, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0408 | triosephosphate isomerase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.3210 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3919 | Escherichia coli | non-essential | goodall |
YDR050C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1303800 | Plasmodium berghei | Essential | plasmo |
TGME49_233500 | Toxoplasma gondii | Probably essential | sidik |
TGME49_225930 | Toxoplasma gondii | Probably essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | decreased time (PATO:0000716) | multi-cellular organism (CARO:0000012) | bloodstream stage (PLO:0040) | inferred from anti-sense experiment (ECO:0000018) | Plasmodium falciparum | No drug identifiers listed for this gene. |
Annotator: | saralph@unimelb.edu.au. | Comment: | 012/Mar/09. | References: | 8552672 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.8
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | triosephosphate isomerase 1 | Compounds | References |
Oryctolagus cuniculus | Triosephosphate isomerase | Compounds | References |
Leishmania major | triosephosphate isomerase | Compounds | References |
Trypanosoma cruzi | triosephosphate isomerase, putative | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
PF3D7_1439900 | purified protein | BRENDA | A protein with this EC number or name or sequence has been purified from Plasmodium falciparum ( 3 ) |
19 literature references were collected for this gene.